A broad US policy shift has begun to reshape the global pharmaceutical landscape, with India facing a subtle but significant strategic constraint. In a proclamation published on April 2, 2026, US President Donald Trump invoked Section 232 of US trade law to impose taxes on imported patented pharmaceuticals, claiming that a reliance on foreign medicinal supplies jeopardises national security. The measure will not affect all participants equally—this is where the real story resides.

The centrepiece is a headline-grabbing 100% charge on certain imported patented pharmaceuticals and crucial chemicals, but the structure is more complex than it appears. The policy establishes numerous pathways. Companies who commit to transferring manufacturing to the United States may face a 20% tariff reduction, while those that enter Most Favoured Nation (MFN) pricing agreements—promising to sell at their lowest worldwide price—may be eligible for even lower or zero-duty access for a limited time. Other assistance comes through current or negotiated trade agreements, notably with US partners.

This means that the advantage is defined not just by country, but also by alignment, agreements, and compliance.

"I have determined that it is necessary and appropriate to impose a 100 percent ad valorem duty rate," the proclamation reads, while also describing ways for businesses to escape the full burden. Another phrase emphasises the rationale: imports are "in such quantities...as to threaten national security."

The United States' worry is based on supply risk. According to official data, around 53% of patented medications used domestically are manufactured outside of the country, with only 15% of crucial chemicals—known as active pharmaceutical ingredients or APIs—made in the United States. APIs are the essential chemical components that give a medicine its effect. If their supply is disturbed, treatment chains may collapse.

For India, immediate relief is obvious but conditional. Generic drugs are still not subject to tariffs "at this time." This safeguards a key export engine, as Indian manufacturers sell a large proportion of low-cost pharmaceuticals to the United States market. However, the regulation explicitly allows for future review, adding an element of ambiguity.

India's objectives for innovation are under increasing pressure. Over the last decade, Indian pharmaceutical companies have made significant investments in the discovery of new medications, also known as New Chemical Entities (NCEs), a time-consuming and costly procedure in which scientists examine thousands of molecules before one shows promise. In practice, it frequently entails years of trial and error in laboratories, watching molecules react under controlled conditions until one eventually works.

Under the new US structure, such inventions are not automatically prohibited or taxed at the maximum rate. However, without alignment through onshoring, price agreements, or partnerships, they are more likely to face higher tariff rates than products from enterprises already incorporated into US-linked frameworks or bilateral agreements. This creates a structural disadvantage, albeit not an outright barrier.

Preferential access offered to partners such as the European Union, Japan, and the United Kingdom does not fall under a simple flat tariff category. Instead, it incorporates existing or evolving agreements, tariff ceilings, and negotiated paths, including pricing promises. The end effect is a system in which some players begin closer to conformity, while others must actively negotiate their entry.

This is when the pressure on Indian companies increases. Many companies may now explore moving sections of their production or research operations to the United States—not as a statutory necessity, but as an economically rational response. The trade-off is significant. Relocation increases expenses, however MFN pricing might reduce profitability globally.

The rollout is staggered. Tariffs are set to go into force in late July 2026 for certain enterprises and September 2026 for others, with a longer window—extending until 2029—for businesses to negotiate agreements and adapt operations.

For Indian officials and industrial executives, the challenge is more acute than ever. Continue to dominate the worldwide generics area, or shift your approach to compete in high-value innovation in a system that increasingly benefits closeness to the US market.

The question is no longer about whether the rules have changed. The question is whether India can change quickly enough to remain competitive at both ends of the pharmaceutical value chain.